1. Lecrubier Y. The impact of comorbidity on the treatment of panic disorder. J Clin Psychiatry 1998;59:11–14.
2. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8–19.
3. Charney DS, Drevets WC. Neurobiological basis of anxiety disorders. In: Davis KL, Charney D, Coyle JT, Nemeroff C, editors. Neuropsychopharmacology: the fifth generation of progress. Philadelphia, PA: Lippincott Williams & Wilkins; 2002. p. 901–930.
4. Davis M. Neural circuitry of anxiety and stress disorders. In: Davis KL, Charney D, Coyle JT, Nemeroff C editors. Neuropsychopharmacology: the fifth generation of progress. Philadelphia, PA: Lippincott Williams & Wilkins; 2002. p. 931–951.
5. Shelton RC. Antidepressant therapy: new targets for drug development. Expert Opin Ther Pat 2001;11:1711.